Results 131 to 140 of about 681,398 (156)

<i>NTRK</i> Gene Fusions: A Compendium of Fusion Partners and Tumor Types. [PDF]

JCO Precis Oncol
Yang SR, Repetto M, Rudzinski ER, Li MM, Roy A, Gutstein L, Huang K, Wu J, Glade Bender J, Brega N, Buchberg AM, Bernard-Gauthier V, Hong DS, Drilon A, Laetsch TW.   +14 more
europepmc   +1 more source

Outcomes of elective discontinuation, retreatment, and alternatives to surgery in childhood fibrosarcoma. [PDF]

Transl Pediatr
Ibáñez-Navarro A, Villanueva Freije A, Aguirre-Portolés C, Pérez-Martínez A.   +3 more
europepmc   +1 more source

Real-World Evidence for Oncology Patients With Rare <i>NTRK</i> Gene Fusions: Final Results From the German Multicenter Patient Cohort Study REALTRK. [PDF]

JCO Precis Oncol
Potthoff K, Lange S, Seufferlein T, Heinrich K, Claus R, Bleckmann A, Zaiss M, Vannier C, Grebhardt S, Koszinowski S, Hillebrand LE, Ringwald K, Kasenda B.   +12 more
europepmc   +1 more source

Epigenetic Regulation of Trk Receptors and Neurotrophic Signalling in Neuroblastoma: Mechanisms, Plasticity, and Therapeutic Opportunities. [PDF]

Int J Mol Sci
Siddi C, Balla J, Fadda P, Dedoni S.
europepmc   +1 more source

Development of PROTACs for targeted degradation of oncogenic TRK fusions. [PDF]

RSC Chem Biol
Kumar S, Jiang J, Donald-Paladino MS, Chen J, Gutierrez A, Federation AJ, Szulzewsky F, Holland EC, Ferguson FM, Nabet B.   +9 more
europepmc   +1 more source

Regulatory Perspectives in Precision Oncology: Challenges and Opportunities for Tyrosine Receptor Kinase (NTRK) Inhibitors in Non-small Cell Lung Cancer (NSCLC). [PDF]

Cureus
Gainor J, Popat S, Bundy L.
europepmc   +1 more source

Targeting druggable kinases in neuropathic pain. [PDF]

NPJ Drug Discov
Benson H, Kaur K, Ahmed MS.
europepmc   +1 more source

Infant-Type Hemispheric Glioma With NTRK Fusion Responds to Larotrectinib. [PDF]

Cureus
Jain PV, Rumler S, North P.
europepmc   +1 more source

Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges. [PDF]

Curr Oncol
Habib R, Arnold E, Obi T, Vizeacoumar FJ, Ahmed S.   +4 more
europepmc   +1 more source

Refining first-line therapy in ALK-positive non-small cell lung cancer: final overall survival from the ALEX trial and an evolving treatment landscape. [PDF]

J Thorac Dis
Boshkos M, Parma M, Singhi EK.
europepmc   +1 more source